3 5,, 2004 380-1
1 3 2 5 3 20 6 4 9 5 REACH 13 6 14 7 16 8 16 9 17 10 Science 18 11 FDA 18 12 20-2
1 1993 2 28 2005 10 12 8 Jacques Gorlin Mariana Gumalius 5 15-3
Mariana Gumalius 1 2 10 20 8 12 10 Mariana Gumalius Elaine wu 1984 5 14 3 7 6 1993 15 20 2002-4
6 1993 2000 285 1999 109 1998 511 2-5
http://www.ebiotrade.com/ 3 20 20 20mg 20 6.5 20mg 30 9.8 20mg 10 21.2 20mg 30 56.6 6-6
20 20 2002 2004 20 2003 10 2003 4 199 6 199 199 10 2003-7
2004 9 1 2004 10 23 4 4 199 http://www.ebiotrade.com/ GMP - 8
4 300 5% 5% 70% SARS 13 21 11 3 3-9
13 8-10
1 2 3-11
4 5 INTERNET WTO 1958 GATT WTO TRIPS - - - 12
(http://www.ebiotrade.com/) WHO 5 REACH 2002 REACH 1981 9 40 3 80 15 5 2003 5 7-13
REACH 7 16 17 10 31 2004 1 21 WTO TBT COM 2003 644final 2005 2006 REACH 730 5 REACH 1 1 5 5 10 REACH 6 BfArM PEI Paul Ehrlich Institut - 14
Testallergenen 5 CEP CEP DMF DMF 2004 24 2005 10-15
30 15 30 GMP 2004 24 7 2004 7 1 REACH REACH GMP REACH GMP 8-16
5 NICVAX NICVAX TA-NIC 1997 (sdrug.com) 2005 2 28 77-17
9 Ujjal Dosanjh 80% the Patented Medicine Prices Review Board PMPRB 1 hc360 10 Science Science Jordan Paradise 1000 38%, 11 FDA - 18
FDA 2005 3 14 FDA FDA FDA FDA FDA - 19
: FDA 12-20
- 21
GSP 123-22